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Abstract
Members of the protein kinase C (PKC) family have long been studied for their contributions to
oncogenesis. Among the ten different isoforms of this family of serine/threonine kinases, protein
kinase Cε (PKCε) is one of the best understood for its role as a transforming oncogene. In vitro,
overexpression of PKCε has been demonstrated to increase proliferation, motility, and invasion of
fibroblasts or immortalized epithelial cells. In addition, xenograft and transgenic animal models have
clearly shown that overexpression of PKCε is tumorigenic resulting in metastatic disease. Perhaps
most important in implicating the epsilon isoform in oncogenesis, PKCε has been found to be
overexpressed in tumor-derived cell lines and histopathological tumor specimens from various
organ sites. Combined, this body of work provides substantial evidence implicating PKCε as a
transforming oncogene that plays a crucial role in establishing an aggressive metastatic phenotype.
Reviewed here is the literature that has led to the current understanding of PKCε as an oncogene.
Moreover, this review focuses on the PKCε-mediated signaling network for cell motility and
explores the interaction of PKCε with three major PKCε signaling nodes: RhoA/C, Stat3 and Akt.
Lastly, the emerging role of PKCε as a tumor biomarker is discussed.
Introduction to the protein kinase C (PKC) 
family
Several decades of research have documented that mem-
bers of the protein kinase C (PKC) family of serine/threo-
nine kinases are key signaling molecules involved in
diverse cellular functions. Comprised of ten different iso-
forms, the PKC family is divided into three groups accord-
ing to structural features and activation requirements. The
classical isoforms (α, βI, βII, and γ) have an intact C1 dia-
cylglycerol/phorbol ester binding domain and C2 calcium
binding domain and thus require phospholipids and cal-
cium for activation. The second group contains the novel
isoforms (δ, ε, θ, and η,), which do not require calcium for
their activation. The third group contains the atypical iso-
forms (ζ, and ι/λ), which can be activated in the absence
of diacyglycerol and calcium.
Some of the many cellular processes regulated by PKCs
include apoptosis, proliferation, migration, motility,
chemo-resistance and differentiation (reviewed in [1-4]).
Most notably, PKCs have been extensively studied in the
context of oncogenesis. This body of literature first arose
from work done in the 1980s when PKC was identified as
an intracellular receptor for the tumor promoting phorbol
esters [5-7]. Since these early reports, the discrete roles of
many PKC isoforms in oncogenesis have been studied. It
is now appreciated that each of the ten PKC isoforms is
unique in its contribution to cancer development and
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progression. For example, within the context of an animal
model of skin cancer, overexpression of PKCα has no
effect on tumorigenesis [8], while the delta isoform sup-
presses tumor development [8,9]. In contrast, the epsilon
isoform is severely oncogenic and promotes metastatic
squamous cell carcinoma [10]. In other model systems,
the varying roles of PKC isoforms have also been docu-
mented. PKCα has been described as an essential pro-pro-
liferative and survival molecule in glioma cell lines [11].
Recently, PKCα was reported as a mediator of cell prolif-
eration in head and neck cancer cell lines and as a predic-
tive biomarker for disease-free survival in head and neck
cancer patients [12]. Similarly, the iota isoform is now
appreciated for its role in promoting cell motility/inva-
sion [13] and proliferation [14].
Among the many PKC family members, several isoforms
have been found to have paradoxical and tissue specific
roles in tumor initiation. Of note, the contribution of
PKCδ to oncogenesis has been contested through conflict-
ing experimental findings. For example, several lines of
evidence support PKCδ as an anti-proliferative molecule.
These data include the work done in animal models of
skin cancer [9] as well as the finding that PKCδ expression
can revert transformed rat colonic epithelial cells towards
a wild-type phenotype [15]. In contrast to this body of
work, others have found that PKCδ promotes the survival
of breast and lung cancer cells [16,17]. This discrepancy
speaks to the complexity of understanding the roles of
PKC family members in the context of oncogenesis. From
the abundant literature on PKCs, it is clear that the func-
tion of PKC isoforms in oncogenesis is highly tissue
dependent and thus it is critical to understand the role of
each PKC isoform in the proper cellular context.
PKCε as a transforming oncogene
In one of the first experimental works aimed specifically at
exploring the oncogenic potential of PKCε, Mischak and
colleagues overexpressed PKCε in NIH 3T3 fibroblasts
[18]. These authors found that upon PKCε overexpres-
sion, cells grew at a faster rate and with increased densities
and confluence. Cells transfected with PKCε also demon-
strated an increased ability to grow in soft agar in the
absence of phorbol 12-myristate 13-acetate (PMA). In
vivo, 100% of mice injected with PKCε overexpressing
NIH 3T3 cells developed tumors. Mice injected with
PKCδ-expressing or untransfected NIH 3T3 cells did not
develop tumors. Combined, these findings were among
the first evidence demonstrating PKCε as an oncogene.
In the same year, Cacace and coworkers found that over-
expression of PKCε in fibroblasts leads to an oncogenic
phenotype in vitro and in vivo [19]. Similar to these earlier
findings, Perletti et al. found that overexpression PKCε in
FRC/TEX CL D (D/WT) colonic epithelial cells led to a
metastatic phenotype which included morphological
changes, increased anchorage independent growth and
marked tumorigenesis in a xenograft model [20]. These
reports set the stage for our current understanding of PKCε
as a transforming oncogene.
Proliferation and cell survival
Many of the details about the pro-tumorigenic signaling
pathways modulated by PKCε have been elucidated. For
example, PKCε is known to exert its oncogenic effects
through modulation of the Ras signaling cascade [21-24],
one of the best characterized signaling pathways in all of
cancer biology (reviewed in [25]). Among the many
downstream effects of Ras signaling includes increased
cell cycling via up-regulation of cyclin D1 [26-29]. PKCε
expression has been linked to activation of the cyclin D1
promoter and increased growth rates [30,31]
In addition to its influence on Ras signaling, PKCε has
also been implicated in anti-apoptotic signaling pathways
through the modulation of caspases and Bcl-2 family
members [32-38]. Similarly, PKCε exerts its pro-survival
effects by activating Akt/PKB [39-41]. Like the Ras signal-
ing pathway, the pro-proliferative effects of Akt signaling
are well described in the context of oncogenesis (reviewed
in [42]). The role of PKCε in proliferation and survival sig-
naling pathways has been extensively reviewed by Basu
and Sivaprasad [43].
Motility and invasion
In addition to promotion of proliferation and escape
from apoptosis, dysregulation of cellular adhesion and
motility are key components of a metastatic phenotype.
The ability of a cell to migrate is essential for invasion of
surrounding tissues as well as spread to distal sites. It is
now appreciated that overexpression of PKCε leads to a
highly motile and invasive phenotype. For example, Tach-
ado and coworkers reported that expression of PKCε pro-
motes a polarized cell morphology and in vitro cell
invasion [44]. Moreover, these authors found that mice
inoculated with NIH 3T3 cells overexpressing PKCε expe-
rienced tumor invasion of nearby tissues as well as liver
metastases. Consistent with these findings, our group
demonstrated that knockdown of PKCε with RNAi
decreases in vitro invasion and motility [45,46], as well as
incidence of lung metastases in a pre-clinical animal
model of breast cancer [45].
Specific details of how PKCε modulates cell motility are
beginning to emerge. It is now known that PKCε contains
an actin binding domain [47]. Motile cells overexpressing
PKCε have been observed to extend lamepidia-like protru-
sions [44]. The ability of PKCε to promote F-actin assem-
bly in a cell-free system is compelling evidence for the role
of PKCε in modulating outgrowth through actin polymer-Molecular Cancer 2009, 8:9 http://www.molecular-cancer.com/content/8/1/9
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ization [48]. PKCε has been observed to translocate to the
cell membrane during the formation of focal adhesions
[49]. This initial process of cellular adhesion to the extra-
cellular matrix is known as cell spreading. During spread-
ing, a cell undergoes a redistribution of adhesion and
structural molecules. Once a cell has spread it may then
take part in contact dependent functions such as motility.
The expression of β1-integrin cytoplasmic domain con-
nected to a non-signaling transmembrane domain inhib-
its the process of cell spreading [50]. PKCε is sufficient to
rescue cell spreading in cells expressing non-signaling β1-
integrin molecules [50]. This finding suggests PKCε sign-
aling downstream of β1-integrin engagement with the
extracellular matrix.
Ivaska et al. reported that PKCε plays a role in the return
of endocytosed β1-integrin molecules to the plasma
membrane [51]. The inhibition of PKCε with bisindolyl-
maleimide I (BIM-I) leads to an accumulation of intercel-
lular β1-integrin/PKCε containing vesicles. Without the
recycling of integrins, a necessary process for the advance-
ment of cell's leading edge, a decrease in motility was
observed. It is now known that phosphorylation of the
cytoskeletal protein, vimentin, by PKCε is needed for the
regulated release of integrin from recycled vesicles back to
the plasma membrane [52].
In glioma cells, PKCε has also been found to be an impor-
tant promoter of cell migration [53,54]. In adhesion
assays, PKCε overexpressing cells were shown to adhere in
greater numbers to laminin, vitronectin and fibronectin as
compared to control cells [54]. PKCε expression was also
responsible for lamellipodia formation. Similar to other
reports, these authors found that PKCε interacts with β-
integrin chains. In addition, it was found that RACK1, a
scaffold protein associated with PKCε, is also a require-
ment of cell motility and forms a complex along with
PKCε and β-integrin. This same group also found that
extracellular-signal related kinase (ERK) localizes to sites
of focal adhesions [53]. In PKCε overexpressing clones, an
increase in the amount of activated phospho-ERK, a
downstream molecule in the Ras signaling cascade, was
observed. Cells transfected with an anti-sense PKCε cDNA
showed the opposite pattern. Moreover, upon inhibition
of the ERK signaling pathway, cells were less adhesive and
motile in response to PMA stimulation.
Our laboratory reported that PKCε-driven cell motility is
mediated at least in part due to downstream activation of
small Rho GTPases, specifically RhoA and/or RhoC
[45,46]. RNAi-mediated knockdown of PKCε in head and
neck cancer cells with elevated endogenous PKCε levels is
sufficient to significantly impair cell motility [46]. Moreo-
ver, reconstitution of constitutive active RhoA or RhoC in
these PKCε-deficient head and neck cancer cells rescued
the loss-of-function motility defect providing direct evi-
dence that RhoA and RhoC is downstream of the PKCε
signaling cascade [46]. Our work, although novel, merely
adds to the published literature on the linear signaling
pathways mediated by PKCε to modulate cell motility. It
is clear that signal transduction pathways must be
approached through a systems biology perspective to cap-
ture the conditions necessary to drive a particular cellular
event. To this end, we constructed a schematic model of
the PKCε signaling network for cell motility using pub-
lished results from our laboratory and other laboratories
(Figure 1). This model contains three highly intercon-
nected PKCε signaling nodes, Akt, RhoA/RhoC, and Stat3,
with multiple positive and negative points.
Akt is activated through two phosphorylation events.
PDK1 phosphorylates Akt at threonine 308 and recently,
PKCε was identified as the kinase that phosphorylates Akt
at serine 473 leading to full Akt activation [55]. There is
evidence that Akt phosphorylates and activates PAK1 to
enhance cell migration [56,57]. Interestingly, PAK1 was
shown to inhibit the activity of NET1, a RhoA-specific
guanine nucleotide exchange factor, suggesting that PAK1
will inhibit RhoA activation under certain conditions
[58]. PAK1 phosphorylates myosin light chain kinase
(MLCK) resulting in decreased MLCK activity and myosin
light chain (MLC) phosphorylation in epithelial cells
[59]. MLC is a component of myosin and involved in the
assembly of actomyosin filaments for contraction. MLC is
phosphorylated at Ser19 by myosin light chain kinase
(MLCK) and Rho-kinase, a downstream effecter of RhoA
and RhoC, to enhance myosin ATPase activity and muscle
contraction [60,61]. PAK1 and Rho-kinase also directly
regulates the activation of LIM domain kinases (LIMKs), a
family of two serine/threonine kinases involved in actin
cytoskeleton regulation. PAK1 phosphorylates LIMK1 at
Thr508 and Rho-kinase, a downstream effector of RhoA
and RhoC, phosphorylates LIMK2 at Thr505 resulting in
an increase in LIMK1 and LIMK2 activity, respectively
[62,63]. Activated LIMK1/LIMK2 inhibits the actin depo-
lymerizing activity of cofilin by phosphorylation at the
Ser3 residue of cofilin resulting in formation of stress fib-
ers and focal adhesions for cell migration [63-65].
Recent reports demonstrated that PKCε directly phospho-
rylates Stat3 at Ser727 resulting in an increase in nuclear
translocation and transcriptional activation of Stat3 [66-
68]. Additionally, RhoA activation, mediated at least in
part through Rho-kinase, results in an increase in Stat3
phosphorylation at Tyr705 and Ser727 and nuclear trans-
location [69]. Interestingly, Stat3 was reported to directly
bind to the tubulin-binding region of stathmin to attenu-
ate binding of stathmin to tubulin resulting in microtu-
bule stabilization [70]. Stathmin is a ubiquitous cytosolic
phosphoprotein involved in the regulation of the micro-Molecular Cancer 2009, 8:9 http://www.molecular-cancer.com/content/8/1/9
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tubule filament system by promoting tubulin filament
depolymerization. Stathmin was reported to be phospho-
rylated at four serine residue, Ser16, Ser25, Ser38, and
Ser63 by various kinases, including cyclin-dependent
kinase, MAP kinase, and PKA [71,72]. Phosphorylation of
stathmin at Ser16 and Ser63 was found to be necessary to
optimally prevent stathmin from binding to tubulin
resulting in microtubule stabilization [73].
In silico analysis using the Genomatix-MatInspector soft-
ware identified Stat3 and serum response factor (SRF)
transcription factor binding sites in the predicted PKCε
promoter region. Stat3 nuclear translocation and tran-
scriptional activity are regulated directly by PKCε and
Rho-kinase [68]. In addition, SRF-mediated transcription
is activated in response to RhoA and RhoC activation
[74,75]. These observations is attractive from a molecular
mechanism point of view as it suggests that a feed-forward
mechanism, through PKCε-mediated increases in Stat3
and SRF transcriptional activities, may result in a sus-
tained activation of the PKCε signaling network. Moreo-
ver, it is not known at this time, the contribution and
requirement of each PKCε signaling module for promot-
ing a motile cell phenotype. It is possible that there is
redundancy in this system and that perhaps, only select
nodes are indispensable to drive PKCε-mediated cell
motility in cancer cells.
Overexpression in various cancer types
The role PKCε in specific cancer types has been explored
in great detail. To date, the overexpression of PKCε has
been observed in a large number of cancer types (Table 1).
The etiology of PKCε overexpression, however, remains
elusive. To the best of our knowledge, no publications
exist which document mutations responsible for PKCε
overexpression. One group, however, has found 2p21 to
Schematic model illustrating the PKCε signaling network for cell motility Figure 1
Schematic model illustrating the PKCε signaling network for cell motility. Arrow Black lines represent activation 
and Circle red lines represent inactivation. Arrow dashed lines represent putative interactions based on in silico transcription 
factor binding prediction software. All interactions are based on published literature as described in the text.
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be amplified in the rearranged DNA of WRO thyroid car-
cinoma cell lines and thyroid tumor samples [76,77]. This
region on the short arm of chromosome 2 is home to the
PKCε gene. The clinical value of this knowledge, however,
is yet to be determined. Regardless of the origin of PKCε
overexpression, it is clear that this protein is emerging
through the literature as an important biomarker and
potential drug target for many cancer types.
Our laboratory was the first to report that PKCε plays a
causative role in establishing an aggressive, invasive, and
motile phenotype in breast cancer [45]. Inhibition of
PKCε by RNAi in MDA-MB231 cells, a highly metastatic
breast cancer cell line with elevated PKCε levels, was suffi-
cient to dramatically decrease cell proliferation, anchor-
age-independent colony formation, invasion, and
motility in vitro. Similarly, MDA-MB231 cells transfected
with RNAi against PKCε showed decreased tumor growth
kinetics and a reduced incidence in the number of lung
metastases in an orthotopic model of breast cancer. More-
over, using high-density tissue microarrays with tumor
specimens from invasive ductal breast carcinoma patients,
elevated PKCε was associated with high histologic grade,
positive Her2/neu receptor status, and negative estrogen
and progesterone receptor status. In addition, elevated
PKCε was demonstrated to be a prognostic biomarker of
poorer overall and disease-free survival.
PKCε has also been implicated in head and neck squa-
mous cell carcinoma (HNSCC). In a small prospective
study of 29 patients with primary squamous cell carcino-
mas of the oral cavity, elevated PKCε levels were signifi-
cantly associated with disease relapse and decreased
overall survival [78]. The authors of this study concluded
that elevated PKCε may serve as a prognostic marker of
aggressive disease in oral cancers. Consistent with this
work, our laboratory reported that PKCε is elevated in a
panel of HNSCC cell lines [46]. In vitro, HNSCC cell lines
with high endogenous PKCε levels are associated with a
highly invasive and motile phenotype. Additionally,
RNAi-mediated silencing of PKCε in HNSCC with high
endogenous PKCε levels resulted in a marked reduction in
cell invasion and motility.
Elevated levels of PKCε have been documented in lung
cancers. In the small cell lung carcinoma cell line (SCLC)
NCI-N417, a constitutively active catalytic fragment of
PKCε has been reported [79]. In non-SCLC cell lines
(NSCLC), PKCε is associated with a chemo-resistant phe-
notype [32]. Aberrant PKCε levels have also been
observed in histopathological lung tumor specimens [80].
Bae and colleagues have found PKCε to be overexpressed
in >90% of NSCLC histological sections as compared to
normal controls.
Like our group's work in both breast and head and neck
cancer, inhibition of PKCε in NSCLC cells leads to
decreased aggressive phenotype in vitro [80]. More specif-
ically, cells treated with a dominant negative version of
PKCε showed marked decreases in cell proliferation and
anchorage-independent growth. Treatment of NSCLC
cells with this dominant negative, or a RNAi against PKCε,
resulted in a decrease in G1-S cell cycle transition. The
authors attribute this arrest to an induction of p21/Cip1,
a cyclin-dependent kinase inhibitor. From these results
the authors point to PKCε as promoting dysregulation of
the cell cycle in NSCLC.
In an animal model of prostate cancer, overexpression of
PKCε in androgen-dependent LNCaP cells resulted in a
transformation to an androgen-independent phenotype
[81]. In both wild-type and castrated male nude mice,
these cells undergo aggressive tumor growth. In vitro,
PKCε overexpression conferred an increase in prolifera-
tion as well as resistance to apoptosis. Elevated PKCε lev-
els have also been documented in clinical prostate cancer
samples. One investigation found PKCε to be overex-
pressed in specimens of early prostatic adenocarcinomas
obtained at time of radical prostatectomy [82]. As deter-
mined by high-density tissue microarrays, other investiga-
tors found increasing PKCε levels to correlate with tumor
grade [67]. PKCε has also been found to be overexpressed
in samples from other tissues of the urogenital tract. High
PKCε levels have been detected in renal carcinoma cells
[83] and in tumor specimens from the urinary bladder
[84]. In the latter, increasing PKCε cells correlated with
tumor grade [84].
PKCε has been shown to be an important player in driving
squamous cell carcinoma (SCC) of the skin. Transgenic
expression of PKCε under the control of the human kera-
tin 14 promoter/enhancer has been shown to result in an
18-fold increase in PKCε [11]. This overexpression of
PKCε drove the development of SSC in these animals with
40% of transgenic mice developing SSC of the skin as
compared to 7% of controls. Histopathology revealed
malignant invasion of tumors as well as metastases to
regional lymph nodes. Overexpression of PKCε in FVB/N
Table 1: PKCε overexpression in histopathological specimens
Organ Reference
Bladder 84
Brain 87
Breast 45
Head and Neck 78
Lung 80
Prostate 67, 82Molecular Cancer 2009, 8:9 http://www.molecular-cancer.com/content/8/1/9
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mice has also been demonstrated to predispose mice to
SCC after ultra-violate radiation (UVR) exposure [85].
PKCε has been studied in malignancies of the central
nervous system. In glioblastoma cell cultures, PKCε was
found to be elevated between three to thirty times that of
normal protein levels [86]. Consistent with this observa-
tion, Sharif and Sharif have reported that PKCε is overex-
pressed in a large number of astroglial cell lines [87].
Similarly, these authors report that PKCε is overexpressed
in histological samples from anaplastic astrocytoma,
globlastoma multiforme and gliosarcoma tumor samples.
Interestingly, PKCε was not found in polocytic astrocyto-
mas samples, a grade I malignancy.
The role or PKCε in myelo- and lympho- proliferative dis-
eases has not been well studied. In one animal model,
overexpression of PKCε in the epidermis of mice results in
a myeloproliferative disease characterized by gross
increases in the number eiosiniphils and neutrophils [88].
These mice show marked increases in serum levels of
interleukin-5, interleukin-6 and G-CSF as well as infiltra-
tion of the lungs, liver and kidneys by the proliferative
myeloid cells. The authors postulate that the overexpres-
sion of PKCε in these mice leads to an induction of
cytokines which in turn promotes disease. Although this
model system may prove to be important in studying
myeloproliferative disease, the clinical significance of
PKCε in this setting is still uncertain. At present, there is
no existing literature to document PKCε overexpression in
samples from patients with hematopoetic cancers. As
such, the role of PKCε in such diseases of the hematopo-
etic compartment is unclear.
Conclusion
Dysregulation of PKCε is a frequent genetic event associ-
ated with oncogenesis from multiple organ sites, includ-
ing breast, prostate, and head and neck. PKCε is elevated
in cell lines derived from patients and primary tumor
specimens in numerous cancers providing substantial evi-
dence for PKCε as a general transforming oncogene. Evi-
dence to support PKCε as a prognostic biomarker for
disease-recurrence and overall survival is beginning to
emerge. Additional work is needed before the utility of
PKCε as a value-added tool in the clinical decision-mak-
ing process can be applied in the clinic. There is accumu-
lating literature on the PKCε signaling pathway involved
for cell invasion, motility, proliferation and survival; how-
ever, a system biology approach will be needed to begin
to understand the conditions necessary to drive PKCε-
mediated oncogenesis. Detailed understanding of the glo-
bal PKCε signaling network, including temporal and
intensity dynamics, is essential to identify "druggable"
points in the signaling cascade to optimize therapeutic
efficacy and minimize unwanted adverse effects. This
approach will lead to the development of novel molecu-
larly-targeted anti-cancer therapeutics which hopefully
will improve the prognosis or quality of life for patients
with aggressive metastatic disease.
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